title: Long-term outcome of early stage prostate cancer treated with brachytherapy analysis after a mean follow-up of 7 years.
abstract: OBJECTIVE
  To investigate the long-term efficacy of (125)I brachytherapy in early-stage prostate cancer and to identify correlating factors.
  
  
  METHODS
  This study included 117 cases of early stage prostate cancer. The patients ranged in age from 51 to 84 years, with a mean of 73 years. The features of the study population were as follows: the PSA ranged from 0.4 to 47.6 ng/ml (median, 14.7); the Gleason score ranged from 4 to 9 (mean, 6.4); the clinical stage ranged from T1b to T2c; and the positive biopsy rate ranged from 0.08 to 1.0 (mean, 0.45). The mean D90 was 142 Gy and ranged from 106 Gy to 170 Gy. The numbers of low-risk, intermediate-risk and high-risk prostate cancer cases were 22, 29 and 66, respectively. The biochemical no evidence of disease (bNED) rate and overall survival were recorded. Factors that correlated with the outcomes were evaluated.
  
  
  RESULTS
  With a mean follow up of 84 months, 33 cases had biochemical recurrence, with a bNED rate of 72%. The overall survival rate was 90%, and the cancer-specific survival rate was 97%. The bNED rates in the low-risk, intermediate-risk and high-risk groups were 86%, 79% and 64%, respectively (P = 0.040). The patients with PSA <20 ng/ml, a positive biopsy rate lower than 0.5, and D90 ≥ 140 Gy had lower biochemical recurrence (P = 0.028, 0.006, 0.009, respectively).
  
  
  CONCLUSIONS
  The long-term efficacy of (125)I brachytherapy in early stage prostate cancer was shown. bNED is related to risk stratification, PSA level, positive biopsy rate and D90.
authors.affiliation: Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730 China.
authors.forename: Weigang
authors.initials: W
authors.lastname: Yan
authors.affiliation: Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730 China.
authors.forename: Jian
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730 China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730 China.
authors.forename: Zhien
authors.initials: Z
authors.lastname: Zhou
authors.affiliation: Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730 China.
authors.forename: Zhipeng
authors.initials: Z
authors.lastname: Mai
authors.affiliation: Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730 China.
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Ji
authors.affiliation: Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730 China.
authors.forename: Hanzhong
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
authors.forename: Fuquan
authors.initials: F
authors.lastname: Zhang
keywords: Biochemical no evidence of disease; Brachytherapy; Overall survival; Prostate cancer
references.citation: Eur Urol. 2007 Sep;52(3):733-43
references.pmid: 17350750
references.citation: Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):327-33
references.pmid: 17084558
references.citation: World J Urol. 2013 Dec;31(6):1511-7
references.pmid: 23624718
references.citation: Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):789-99
references.pmid: 10386635
references.citation: J Urol. 2005 Mar;173(3):803-7
references.pmid: 15711273
references.citation: Urology. 2007 May;69(5):936-40
references.pmid: 17482938
references.citation: BJU Int. 2013 Jul;112(2):E44-50
references.pmid: 23773225
references.citation: N Engl J Med. 2009 Jun 11;360(24):2516-27
references.pmid: 19516032
references.citation: Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):270-4
references.pmid: 23849693
references.citation: J Urol. 2008 May;179(5 Suppl):S20-4
references.pmid: 18405743
references.citation: Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):25-33
references.pmid: 14697417
references.citation: Brachytherapy. 2012 Jan-Feb;11(1):6-19
references.pmid: 22265434
references.citation: Radiother Oncol. 2009 Nov;93(2):185-91
references.pmid: 19800702
references.citation: Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1336-42
references.pmid: 20605342
references.citation: J Clin Oncol. 2003 Nov 1;21(21):3972-8
references.pmid: 14581419
references.citation: Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):376-81
references.pmid: 20864269
references.citation: Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):349-54
references.pmid: 19467793
references.citation: Urol Oncol. 2014 Jan;32(1):38.e1-7
references.pmid: 23769266
references.citation: Dis Colon Rectum. 2003 Sep;46(9):1277-9
references.pmid: 12972974
references.citation: J Urol. 2003 May;169(5):1643-52
references.pmid: 12686802
references.citation: J Urol. 2007 Nov;178(5):1968-73; discussion 1973
references.pmid: 17868717
references.citation: Radiother Oncol. 2000 Dec;57(3):273-8
references.pmid: 11104885
references.citation: Brachytherapy. 2007 Jan-Mar;6(1):44-8
references.pmid: 17284385